SELLAS Life Sciences Group, Inc.
SLS
$1.41
$0.010.71%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.52M | 13.02M | 13.60M | 14.29M | 13.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.61M | 32.77M | 34.80M | 36.23M | 37.87M |
| Operating Income | -32.61M | -32.77M | -34.80M | -36.23M | -37.87M |
| Income Before Tax | -30.88M | -32.28M | -34.44M | -35.81M | -37.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.88 | -32.28 | -34.44 | -35.81 | -37.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.88M | -32.28M | -34.44M | -35.81M | -37.34M |
| EBIT | -32.61M | -32.77M | -34.80M | -36.23M | -37.87M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.54 | -0.71 | -0.93 | -1.12 | -1.37 |
| Normalized Basic EPS | -0.35 | -0.44 | -0.58 | -0.70 | -0.86 |
| EPS Diluted | -0.54 | -0.71 | -0.93 | -1.12 | -1.37 |
| Normalized Diluted EPS | -0.35 | -0.44 | -0.58 | -0.70 | -0.86 |
| Average Basic Shares Outstanding | 244.69M | 201.50M | 161.60M | 132.32M | 111.06M |
| Average Diluted Shares Outstanding | 244.69M | 201.50M | 161.60M | 132.32M | 111.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |